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Factor H is a regulator of the alternative pathway of
complement, and genetic studies have shown that patients
with mutations in factor H are at increased risk for several
types of renal disease. Pathogenic activation of the
alternative pathway in acquired diseases, such as ischemic
acute kidney injury, suggests that native factor H has a
limited capacity to control the alternative pathway in the
kidney. Here we found that an absolute deficiency of factor H
produced by gene deletion prevented complement
activation on tubulointerstitial cells after ischemia/
reperfusion (I/R) injury, likely because alternative pathway
proteins were consumed in the fluid phase. In contrast, when
fluid-phase regulation by factor H was maintained while the
interaction of factor H with cell surfaces was blocked by a
recombinant inhibitor protein, complement activation after
renal I/R increased. Finally, a recombinant form of factor H,
specifically targeted to sites of C3 deposition, reduced
complement activation in the tubulointerstitium after
ischemic injury. Thus, although factor H does not fully
prevent activation of the alternative pathway of complement
on ischemic tubules, its interaction with the tubule epithelial
cell surface is critical for limiting complement activation and
attenuating renal injury after ischemia.
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The alternative pathway of complement (CAP) is a
phylogenetically ancient arm of the innate immune system
that eliminates invasive pathogens and facilitates the removal
of injured host cells.1 Inadequately controlled CAP activation
has also been implicated in the pathogenesis of a diverse
group of diseases including renal ischemia/reperfusion (I/R)
injury, atypical hemolytic uremic syndrome (aHUS), dense
deposit disease, age-related macular degeneration, and
asthma.2 The important role of this innate immune system
in such a diverse group of diseases suggests that CAP
activation may be a general response to many types of tissue
injury. Furthermore, the important role for CAP activation in
many types of renal disease indicates that the kidney may be
particularly susceptible to injury by this component of the
immune system.
The CAP is continually autoactivated in the fluid phase
through a process called ‘tickover’. Tickover results in the
spontaneous generation of C3b, which can covalently bind to
nearby biologic surfaces. Tissue-bound C3b can then catalyze
further complement activation through the CAP, unless the
reaction is effectively controlled by complement regulatory
proteins (CRPs). Tickover permits the rapid elimination of
pathogens that do not bear CRPs, and expression of CRPs
can be regarded as a recognition mechanism by which the
CAP distinguishes healthy host cells from injured cells and
invasive pathogens.3 However, continual initiation of the
CAP renders host cells critically dependent upon control of
CAP activation by CRPs to prevent spontaneous comple-
ment-mediated injury. Recent studies have demonstrated that
mutations in the CRPs (particularly factor H) are strong
risk factors for aHUS4 and dense deposit disease.5 It is
noteworthy that these system-wide defects in CAP regulation
frequently cause disease that is localized to the kidney, and
the reason for this is currently unknown.
Factor H is an B155-kDa glycoprotein that circulates in
high concentrations (0.3–0.5mg/ml) and regulates CAP
activation in the fluid phase as well as on tissue surfaces.6
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CAP inhibition by factor H on a given tissue requires that
factor H interacts properly with the tissue surface. Several
regions within the factor H protein bind to anionic surfaces,
such as membranes rich in heparan sulfate or sialic acid, as
well as to tissues bearing C3b or C3d.7,8 The polymorphisms
and mutations associated with increased risk for developing
age-related macular degeneration and aHUS most frequently
involve binding regions of factor H and not the complement
regulatory domain.4,9 Activation of the CAP within a given
tissue, therefore, is strongly influenced by the affinity of
factor H for that tissue surface. The tropism of these
diseases for specific organs also suggests that these particular
tissues or cell types are dependent upon factor H for CAP
regulation, and that the relative affinity of factor H for tissue-
specific surfaces is an important factor in the development
of disease.
The CAP also mediates tissue injury in the presence of
fully functional factor H. Ischemic acute kidney injury in
wild-type rodents10,11 and in humans12 is associated with
pathologic activation of the CAP on the basolateral surface of
injured tubular cells. We have found that complement
receptor 1-related gene/protein y (Crry, a rodent analog of
human membrane cofactor protein (CD46) and CR1) is the
only cell surface CRP expressed by proximal tubular epithelial
cells (TECs) in mice, and that IR alters the basolateral
localization of this protein.13 Uncontrolled activation of the
CAP in the setting of reduced surface Crry indicates that
circulating factor H, despite its high protein levels, has a
limited ability to protect the surface of hypoxic TECs, leaving
the ischemic kidney susceptible to pathologic CAP activation.
Given the role of CAP activation in the pathogenesis of such a
wide variety of acquired diseases, it is important to under-
stand the mechanisms by which endogenous complement
regulation can be overwhelmed or subverted. Because
complement activation in ischemic acute kidney injury
occurs almost exclusively via the CAP, it is an informative
model in which to study these mechanisms.
We hypothesized that circulating factor H fails to prevent
CAP activation on hypoxic tubules because of insufficient
affinity for the TECs. To distinguish the role of factor H in
fluid-phase and cell surface CAP inhibition, we have used
several tools, including mice with targeted deletion of the
factor H gene (fH/ mice that lack fluid-phase and surface
CAP regulation by factor H) and a recombinant protein that
competes with one of the binding regions in factor H to block
surface CAP regulation by the protein. We have also
employed a recombinant protein that specifically targets
factor H to sites of iC3b/C3d deposition in order to examine
whether inhibition of CAP by factor H on tissues can be
improved by increasing the affinity of factor H for the cell
surface. Using these tools we have performed in vivo and
in vitro studies to explore the interaction of factor H with the
TEC surface. The results of these studies reveal a complex role
for native factor H in regulating the CAP in acquired
inflammatory diseases and also suggest novel methods for
ameliorating tissue injury.
RESULTS
Targeted deletion of the factor H gene reduces
tubulointerstitial C3 deposition after renal I/R
Mice genetically deficient in factor H develop complement-
mediated glomerular injury as they age.14 Complement
activation in these mice occurs in the fluid phase because
of the lack of regulation by factor H, and levels of circulating
intact C3 are low in these mice (Figure 1a, see Rose et al.15).
C3a levels in the plasma of these mice are elevated, however,
reflecting the high rate of fluid-phase complement activation
(Figure 1b). We subjected fH/mice to renal I/R. The serum
urea nitrogen (SUN) and creatinine values in the fH/ mice
showed a trend toward being lower than in the wild-type
controls (Figure 1c and d), suggesting that the absence of
circulating factor H may be beneficial. The failure of this
protection to reach significance may be because of the
generation of proinflammatory factors in the plasma of
fH/ mice, which counteracts the reduction in tubulointer-
stitial complement activation. Tubular injury was seen in the
outer medullas of fH/ mice and wild-type mice subjected
to I/R (Figure 1e and f). Immunofluorescence microscopy
demonstrated that there was little tubular deposition of C3 in
the fH/ mice, indicating that uncontrolled fluid-phase
activation of C3 in these mice does not leave sufficient intact
C3 to support complement activation on the TEC surface
after I/R. Wild-type mice subjected to renal I/R demonstrated
widespread C3 along the tubular basement membrane of
injured tubules (Figure 1m and n). It has been determined
that the glomerular deposits of C3 fragments in fH/ mice
require the presence of factor I.15 These results indicate that it
is the iC3b fragment of C3 that binds to the glomerular
basement membrane of these mice. It is not clear, however,
why this is the particular site of iC3b deposition.
Factor H limits complement-mediated injury after
renal I/R in wild-type mice
In order to distinguish the function of factor H on cell
surfaces from its fluid-phase function, we generated a murine
recombinant protein (rH19-20) that competitively blocks
binding of the carboxy terminus of factor H to cell surfaces,
similar to the human homolog that has previously been
described.16,17 We confirmed in vitro that the rH19-20
competes with intact factor H in a dose-dependent manner
for binding to C3b-coated host-like cell surfaces (sheep
erythrocytes; Figure 2a). These cells are normally resistant to
complement-mediated lysis, but we found that at concentra-
tions of rH19-20 that inhibit factor H binding, rH19-20
permits CAP-mediated lysis of these cells in a dose-
dependent manner (Figure 2b).
The CAP is activated along the basolateral aspect of
tubules in the outer medulla after renal I/R.13,18 To confirm
that we could achieve comparable levels in vivo, we injected
wild-type mice with 50 mg of biotinylated rH19-20 and
measured serum levels of the protein (Figure 3a). At 15min
after injection of the rH19-20, the serum levels were
0.46±0.06 mmol/l. To test whether circulating factor H is
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Figure 1 |Complement activation is reduced in the tubulointerstitium of mice lacking factor H. fH/mice and wild-type (WT) controls
were subjected to renal ischemia/reperfusion (I/R). (a) Western blot analysis for C3 demonstrated that most of the circulating C3 in fH/
mice is cleaved and is detected as a‘1 or a‘2 fragments. (b) Plasma C3a levels were measured by enzyme-linked immunosorbent assay.
Levels in fH/ mice were higher than in WT mice, and were comparable with those seen in WT mice subjected to renal I/R. (c) Serum urea
nitrogen (SUN) levels and (d) creatinine levels were lower in the fH/ mice, although this only achieved statistical significance for SUNs and
only at 48 h of reperfusion (*Po0.05). Sham-treated animals are presented as 0 h. Tubular necrosis was seen in the kidneys of (e) WT and
(f) fH/mice. Immunofluorescence microscopy for C3b in the kidney of a sham-treated fH/mouse demonstrated (g) heavy deposition of
C3b in the glomeruli, but (h) no C3b in the tubulointerstitium of the outer medulla. In fH/mice subjected to renal I/R, C3b deposition was
still not seen along the tubules of the (i) cortex or (j) outer medulla. In WT mice, C3b was not seen in the glomeruli of (k) sham-treated or
(m) postischemic mice, but was seen in the tubules of the cortex and outer medulla (l and n are sham and postischemia, respectively). n¼ 5
for each group. Original magnification  400 for b and c, staining is with periodic acid-Schiff. Original magnification  200 for d–k.
Glomeruli are indicated with arrowheads.
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functionally important in limiting complement activation at
this location, we subjected wild-type mice to renal I/R, and
then injected them with rH19-20. When biotinylated rH19-
20 was used, the protein could be detected on the injured
tubules in the outer medulla (Figure 3b). The pattern of C3
deposition within the kidney was extensive in both control
animals (Figure 3d) and in mice treated with the rH19-20
(Figure 3e). Mice injected with rH19-20 demonstrated
greater systemic C3a than controls (Figure 3g), indicating a
greater overall degree of complement activation. Semiquan-
titative assessment of tubular C3 did not show a significant
change in mice treated with the rH19-20 (Figure 3f), possibly
because it is difficult to detect the increase of tubulointer-
stitial complement activation above the already extensive
activation seen in wild-type animals.
SUN levels were significantly higher in mice treated with
rH19-20 (Figure 4a), indicating significant functional
impairment in mice treated with rH19-20. Creatinine values
were not significantly higher in mice that received rH19-20
(Figure 4b), although most of the mice that received rH19-20
died before measurements at later time points could be made
(5 mice were treated: 3 died before 48 h of reperfusion and all
died before 72 h of reperfusion). Renal I/R typically causes
injury of the tubules in the outer medulla. Injection of sham-
treated mice had no detectable effect on morphology in the
cortex or the outer medulla (Figure 4c). Control mice
subjected to renal I/R showed tubular injury in the outer
medulla (Figure 4d). In mice treated with rH19-20 after I/R,
however, the injured tubules extended into the cortex (Figure
4e). These results indicate that although the CAP is activated
on the tubules after renal I/R, the overall degree of CAP
activation is limited by factor H.
Native factor H controls complement activation on the
surface of TECs in vitro
We have previously found that there is spontaneous
complement deposition on TECs exposed to 10% homologous
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Figure 2 |Murine rH19-20 (rH19-20) blocks complement
inhibition by factor H on cell surfaces. (a) Cells bearing C3b
were incubated with 20 ng of radioiodinated full-length factor H
and the stated concentration of unlabeled rH19-20. After 20min
at 22 1C, the bound and free radiolabels were separated by
centrifugation of cells through 20% sucrose. The results are
graphed relative to the binding observed with labeled factor H in
the absence of rH19-20. (b) Sheep erythrocytes were incubated in
40% normal mouse serum in the presence of rH19-20 at the
stated concentrations for 20min at 37 1C. The assays contained
5mmol/l MgEGTA to inhibit classical and lectin pathway
activation and restrict activation to the calcium-independent
alternative pathway of complement. Lysis was subsequently
measured by hemoglobin release (A412) after centrifugation to
remove unlysed cells.
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Figure 3 | Surface-bound factor H limits complement activation after renal ischemia/reperfusion (I/R). (a) Mice were injected with
50mg of rH19-20, and serum levels were measured by enzyme-linked immunosorbent assay (n¼ 4). Wild-type mice were subjected to renal
I/R and were treated with biotinylated rH19-20 or with vehicle. Immunofluorescence microscopy demonstrated the protein along the
basolateral aspect of injured tubules (b). No protein was detected in vehicle-treated controls (c). Widespread deposition of C3 was seen in
the tubulointerstitium of (d) vehicle- and (e) rH19-20-treated animals by immunofluorescence microscopy. (f) Semiquantitative scoring of
tubulointerstitial C3 was not significantly greater in mice injected with rH19-20 than in mice injected with vehicle. (g) Plasma levels of C3a
were higher in the mice receiving rH19-20 than in the control animals. n¼ 6 for each group. Original magnification  200 for b–e.
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serum in spite of the factor H present within the serum. The
nature of tissue surfaces influences the efficacy of factor H at
regulating CAP activation on that surface.8 Therefore, we
wanted to test whether complement activation on TECs is
because of the inability of factor H to regulate the CAP on the
surface of these cells. To do this, we purified factor H from
the plasma of wild-type mice (Figure 5a). Zymosan particles
are a known CAP activator, in part because factor H does not
interact well with the particle surface. The addition of
exogenous factor H to serum did not attenuate complement
activation on the surface of zymosan particles, demonstrating
poor interaction of factor H with the zymosan surface
(Figure 5b). However, a recombinant protein that targets the
inhibitory region of mouse factor H specifically to sites of
C3b/iC3b/C3d deposition did fully prevent complement
activation on the zymosan particles (Figure 5b). This protein
comprises C3d-binding region of complement receptor 2
linked to the first five short consensus repeats (the
complement inhibitory region) of factor H (referred to as
CR2-fH;19), a strategy that has previously been utilized for
the targeting of complement inhibitors to sites of comple-
ment activation.20,21 Functional superiority of the CR2-fH
compared with endogenous factor H at preventing comple-
ment activation on a given surface can be attributed to
differential binding of the protein to the specific surface in
question as the two proteins contain the same complement
regulatory moiety.
We next tested the ability of purified mouse factor H and
CR2-fH to prevent complement activation on the surface of
TECs. Increasing concentrations of CR2-fH led to full
inhibition of complement activation on the cell surface
(Figure 5c). Increasing concentrations of factor H also
effectively prevented complement activation on the TEC
surface. Given that factor H was also present in the serum
added to the cells (B500 mg/ml), the final concentrations of
factor H in these experiments were superphysiologic. Never-
theless, these results demonstrate that at a high enough
concentration, factor H is capable of suppressing CAP
activation on the TEC surface.
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Figure 4 | Surface-bound factor H limits complement
activation after renal ischemia/reperfusion (I/R). (a) Serum
urea nitrogen (SUN) levels were higher in the mice treated with
50mg rH19-20 than in vehicle-treated controls at the 24 h time
point (*Po0.05). (b) Creatinine levels were not significantly
different between rh19-20-treated and control mice.
(c) Tubular injury was not seen in sham-treated mice that received
the rH19-20. Tubular necrosis was seen in the outer medullas of
(d) control and (e) rH19-20-treated mice (denoted
with arrows), but the tubular damage in the rH19-20 mice was
more extensive and was seen in the cortex (inset). Sham-treated
animals are presented as 0 h in a and b. Original magnification
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staining is with periodic acid-Schiff. n¼ 6 at 24 h,
n¼ 2 at 48 h.
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Figure 5 | Factor H and CR2-fH inhibit complement activation
on tubular epithelial cells (TECs). (a) Factor H was purified from
the serum of wild-type mice. Its purity and identity were
confirmed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) followed by staining with Coomassie
and western blot analysis. (b) The ability of both factor H and
CR2-fH to inhibit complement activation on zymosan particles
was tested. High concentrations of factor H did not reduce the
amount of C3 deposited on zymosan particles by 10% mouse
serum when assessed by flow cytometry, but CR2-fH did inhibit
complement activation on the surface of the particles.
(c) Increasing concentrations of CR2-fH prevented deposition of
C3 on the surface of TECs exposed to 10% normal mouse serum
when assessed by flow cytometry. (d) Increasing concentrations
of factor H also prevented deposition of C3 on the surface of TECs
exposed to normal mouse serum. The results are the average of
three independent experiments. n¼ 3 for panels b–d. ***Po0.001
versus serum alone. **Po0.01 versus no CR2-fH or factor H.
*Po0.05 versus no factor H.
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Targeted factor H prevents complement activation after
renal I/R
We subjected mice to renal I/R and injected them with 250 or
500 mg of CR2-targeted factor H after 15min of reperfusion.
When CR2-fH was injected into mice that had already been
subjected to ischemia and 16 h of reperfusion (to allow
tubular complement deposition), the CR2-fH could be
detected in the tubulointerstitium (Figure 6a). When injected
shortly after reperfusion, the CR2-fH reduced tubulointer-
stitial C3 deposition. It did not reduce glomerular C3
deposition, although this is not a primary site of complement
activation in this model (Figure 6f and h). We found that the
CR2-targeted factor H ameliorated renal injury after
24 h of reperfusion as assessed by SUN and creatinine
(Figure 7a and b). Lower SUN and creatinine values were
seen in CR2-fH-treated mice out to 72 h of reperfusion, but
the values were not significantly different than control-
treated mice at these time points. Tubular injury was still seen
in the CR2-fH-treated mice (Figure 7c). Targeted agents that
can deliver factor H to the tubulointerstitium can, therefore,
be used to prevent CAP activation in the damaged kidney.
Three mice were treated with high-dose CR2-fH (500 mg).
The high-dose CR2-fH did not confer superior protection to
that achieved with 250 mg. The SUN level was 72±5mg/dl
and the creatinine level was 1.6±0. Tubular injury was still
seen in kidneys of the high-dose group (Figure 7e).
DISCUSSION
The experiments in this study highlight the dual role of factor
H in regulating CAP activation. Circulating factor H prevents
consumption of C3 in the fluid phase, thus maintaining
adequate levels of C3 to support complement activation on
cell surfaces. Consequently, little tubulointerstitial comple-
ment activation was observed in fH/ mice subjected to
renal I/R. On the other hand, the interaction of the carboxy
terminus of factor H with host cells limits CAP-mediated
inflammation on tissue surfaces. When we blocked this
interaction in wild-type mice by treating them with rH19-20,
the mice displayed greater tubulointerstitial complement
activation and more severe injury. Therefore, although
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Figure 6 |CR2-fH prevents complement activation in the kidney after ischemia/reperfusion (I/R). Wild-type mice were subjected to
renal I/R and were then treated with 250 mg of CR2-fH. (a) In mice that received the CR2-fH after 16 h of reperfusion, the protein was
detected within the tubulointerstitium. (b) No protein was detected in vehicle-treated controls. (c) fH/ mice were injected with CR2-fH,
and the protein was detected in the glomeruli (the site of C3 deposition), not in the tubulointerstitium. (d) Vehicle-treated animals have
widespread tubulointerstitial C3 deposition after 24 h of reperfusion. (e) When CR2-fH was injected within 15min of reperfusion, the extent
of C3 deposition was significantly reduced. (f) Little glomerular C3 is detected in mice subjected to I/R. (g) Semiquantitative assessment of
C3 deposition demonstrated that CR2-fH reduced the tubulointerstitial complement activation (n¼ 8–10). (h) Semiquantitative assessment
of the glomerular C3 did not demonstrate any effect of treatment with CR2-fH on glomerular complement activation (n¼ 5). Original
magnification  200 for a, b, d, and e; original magnification  400 for c and f.
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factor H does not fully prevent CAP activation on ischemic
tubules, interaction of factor H with the TEC surface is
critical for limiting complement activation after renal I/R.
The efficacy of factor H at regulating CAP activation on a
given surface is a function of its affinity with that surface.8
High concentrations of factor H did not prevent CAP
activation on zymosan particles (an ‘unreceptive’ surface),
but did prevent CAP activation on TECs in culture. CR2-fH,
which specifically targets the complement regulatory region
of factor H to sites of complement activation, effectively
prevented complement activation on both unreceptive
(zymosan) and receptive (TEC) surfaces. CR2-fH also
effectively prevented CAP activation in the renal tubulointer-
stitium after I/R. This strategy can therefore prevent CAP
activation on tissues where endogenous factor H does not
fully prevent CAP activation because of insufficient quantity
or affinity for the surface, effectively overcoming the
limitations of the native protein.
Mutations and polymorphisms in the tissue-binding
regions of factor H have been linked to several diseases,
including aHUS and age-related macular degeneration.
Conversely, CAP-mediated injury in a host with normal
factor H structure and normal circulating concentrations
suggests a limited affinity of factor H for the target tissue. It is
noteworthy that the CAP has been implicated in models of
several types of renal disease, including renal I/R, aHUS,
dense deposit disease, focal segmental glomerulosclerosis,
anti-neutrophil cytoplasmic antibody-associated vasculitis,
and lupus nephritis.4,10,14,22,23 The predilection of the kidney
to be a primary site of injury may be a consequence of the
particular repertoire of surface complement regulatory
proteins expressed by the different renal cell types, and it
may also be a consequence of the affinity of factor H for the
various structures within the kidney. Complement activation
on ischemic tubules, for example, may be the result of
inadequate complement inhibition by factor H in the setting
of decreased expression of Crry by the TECs.13
The concentration of complement proteins in interstitial
fluid, vascular permeability, and local production of
complement proteins may also be important determinants
of complement activation in the renal tubulointerstitium.
These factors likely contribute to the local balance of
activation. It is possible, for example, that circulating factor
H has only limited access to the TEC cell surface. In that case,
in vitro assays, such as those shown in Figure 4, would not
accurately represent the balance of complement proteins
(activators and inhibitors) present on the TEC surface in vivo.
The optimal design of tissue-targeted therapeutics might,
therefore, have to consider tissue penetration of a molecule as
equally important to target affinity. Local production of C3
by the tubules has been identified as an important factor in
tubulointerstitial complement activation after renal I/R.24
The absence of tubular C3 deposition in the fH/ mice
subjected to I/R, however, suggests that intact circulating C3
(which is reduced in the fH/ mice) may be more important
than locally produced C3 in our model.
Targeted inhibitors such as CR2-fH offer great promise as
therapeutics. Because they specifically bind at sites of
inflammation, they may offer favorable pharmacokinetics
and may also cause less systemic immunosuppression than
untargeted agents.21 A therapeutic such as CR2-fH may be
particularly useful for patients carrying factor H mutations,
or for patients with pathologic CAP activation in tissues for
which circulating factor H has limited affinity. It is notable
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injury was still seen in both (c) vehicle-treated and (d) CR2-fH-treated animals. (e) Tubular injury was still seen in mice treated with a higher
dose of CR2-fH (500 mg). n¼ 11 for vehicle control and n¼ 10 for CR2-fH treatment at the 24 h time point. n¼ 4–6 for the later time points.
Sham-treated animals are presented as 0 h. Original magnification  200 for c–e, staining is with periodic acid-Schiff.
Kidney International (2011) 80, 165–173 171
B Renner et al.: Factor H and renal ischemia/reperfusion o r ig ina l a r t i c l e
that the administration of CR2-fH considerably reduced the
degree of CAP activation in the tubulointerstitium, even in
the presence of circulating factor H. It is also possible that the
administration of additional purified factor H would have been
equally effective, although the concentration of factor H needed
to achieve inhibition on TECs (roughly 1mg/ml in undiluted
serum) would require a considerable amount of protein.
In conclusion, these studies demonstrate that endogenous
factor H plays an important role in limiting CAP activation
on the TEC surface after renal I/R. However, CAP activation
still causes tissue injury in the ischemic kidney, likely because
of insufficient affinity or access of circulating factor H to this
tissue surface. Therapeutic complement inhibitors should be
effective for the treatment of diseases in patients with
mutations in the complement regulatory proteins. These
agents should also be beneficial in diseases, such as ischemic
acute kidney injury, in which the body’s normal complement
regulatory mechanisms do not adequately control activation
of the CAP. The expression of cell surface complement
regulatory proteins and the affinity of factor H to the cell
surface may be unique to each tissue. The common
involvement of the CAP in many different types of renal
disease indicates that complement regulation within the
kidney is easily disrupted or overwhelmed, even in the
absence of mutations in the complement regulatory proteins.
A greater understanding of the function and limitations of
the endogenous regulatory proteins within specific tissue
sites may permit the development of more effective
complement inhibitors, possibly even the development of
tissue-specific therapeutic agents.
MATERIALS AND METHODS
Reagents
Antibodies used in these experiments include a polyclonal goat
antibody for human factor H that crossreacts with mouse factor H
(Quidel Corporation, San Diego, CA), a fluorescein isothiocyanate-
conjugated polyclonal goat antibody to mouse C3 (MP Biomedicals,
Solon, OH), and a monoclonal antibody (mAb 7E9) to a non-C3d-
binding region of mouse CR2.Species-appropriate secondary anti-
bodies from Jackson ImmunoResearch (West Grove, PA) were used
where necessary, and fluorescein isothiocyanate-streptavidin was
used to detect biotinylated proteins in tissues. To purify mouse
factor H, serum from wild-type mice was buffer exchanged with
35mmol/l NaCl and loaded onto a HiTrap heparin HP column (GE
Amersham, Piscataway, NJ). Bound proteins were eluted using a
linear gradient of NaCl and were then separated by size using a
Sephadex 26/60 Superdex 200 column (GE Amersham). The purity
and identity of the isolated protein was verified by Coomassie
staining and by western blot analysis. A recombinant fragment of
mouse factor H encompassing the 19th and 20th short consensus
repeat of the protein was generated in a fashion similar to that
previously described for the equivalent fragment of the human
protein (see Supplementary Materials and Methods online and
Ferreira et al.16).
Protocol for induction of renal I/R
Male C57BL/6J mice were obtained from Jackson Laboratories (Bar
Harbor, ME). Mice with targeted deletion of the gene for factor H
(fH/ mice) were generated as previously described,14 and were
backcrossed 410 generations onto a C57BL/6 background. Mice, 8
to 10 weeks old and weighing 20–25 g, were anesthetized with 60mg/
kg ketamine plus 10mg/kg xylazine (both from Vedco, St Joseph,
MO) injected intraperitoneally. Mice were placed on a heating pad
to maintain their body temperature during surgery. Laparotomies
were then performed and the renal pedicles were located and
isolated by blunt dissection as previously described.10 The pedicles
were clamped with surgical clips (Miltex Instrument Company,
York, PA), and occlusion of blood flow was confirmed by visual
inspection of the kidneys. The clamps were left in place for 24min
and then released. The kidneys were observed for approximately
1min to ensure blood re-flow, then fascia and skin were sutured
with 4–0 silk (United States Surgical, Norwalk, CT). Sham surgery
was performed in an identical fashion, except that the renal pedicles
were not clamped. The mice were volume resuscitated with 0.5ml of
normal saline and kept in an incubator at 29 1C to maintain body
temperature. After 24–72 h, the mice were anesthetized, and blood
was obtained by cardiac puncture. Laparotomy was performed and
the kidneys were harvested. All animal procedures were in adherence
to the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health.
Western blot analysis
Either 100 mg of protein or 1ml of serum was resolved by
electrophoresis with a 10% Bis-Tris polyacrylamide gel (Invitrogen,
Carlsbad, CA) and transferred to a nitrocellulose membrane. Factor
H was detected in the lysates using a polyclonal goat anti-human
antibody (Quidel) diluted 1/100 or a monoclonal antibody to
mouse factor H (Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1/500. Serum C3 was detected using horseradish peroxidase-
conjugated polyclonal goat antibody to mouse C3 (MP Biomedi-
cals). Appropriate secondary antibodies from Jackson Immuno-
research Laboratories were used.
Enzyme-linked immunosorbent assays
Plasma C3a levels were measured by enzyme-linked immunosorbent
assay using monoclonal antibodies and standards from BD
Biosciences (Rockville, MD) according to the manufacturer’s
instructions. Serum levels of biotinylated rH19-20 were measured
by an enzyme-linked immunosorbent assay-type assay. Briefly,
serum samples were diluted 1:50 and incubated with streptavidin-
coated plates (Thermo Scientific, Rockville, IL). The bound rH19-20
was then detected using the antibody to factor H.
SUN and creatinine measurements
SUN and creatinine were measured using an Alfa Wasserman ACE
Chemistry Analyzer (West Caldwell, NJ).
Statistics
Multiple group comparisons were performed using analysis of
variance with post-test according to Tukey. Comparison between
two groups was performed with a two-tailed Student’s t-test. A
P-value of o0.05 was considered statistically significant. Results are
reported as mean±s.e.
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